Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange

Hideaki Uchiyama, Yohei Mano, Akinobu Taketomi, Yuji Soejima, Tomoharu Yoshizumi, Toru Ikegami, Ken Shirabe, Yoshihiko Maehara

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background. A novel immunosuppression protocol using rituximab and plasma exchange treatment was developed for ABO-incompatible living donor liver transplantation (ABO-I LDLT). The aim of this study was to investigate the kinetics of anti-blood type isoagglutinin titers and the number of blood B lymphocytes in ABO-I LDLT with the new protocol and their impact on the outcomes after ABO-I LDLT. Methods. Fifteen patients underwent ABO-I LDLT plus splenectomy with the new protocol between November 2005 and December 2010, and their data were retrospectively analyzed. Results. CD19-positive lymphocytes in the blood rapidly disappeared after rituximab treatment and began to recover approximately 6 months later. Anti-blood type isoagglutinin titers were lowered by pretransplant plasma exchange (2 3∼2 12→2 1∼2 8). Although the anti-donor blood type isoagglutinin titers remained consistently low after transplantation in comparison to the pretreatment levels, they persisted long after LDLT, whereas posttransplant biopsy specimens showed sustained A/B antigens on the graft livers. ABO-I hepatitis C virus-positive patients were prone to acceleration of hepatitis C viremia and cytomegalovirus antigenemia in comparison to the control patients. Conclusions. Although the new protocol for ABO-I LDLT yielded great success with 100% graft survival, the acceptable anti-blood type isoagglutinin titers just before LDLT, and its application to hepatitis C-positive patients must be determined.

Original languageEnglish
Pages (from-to)1134-1139
Number of pages6
JournalTransplantation
Volume92
Issue number10
DOIs
Publication statusPublished - Nov 27 2011

Fingerprint

Plasma Exchange
Living Donors
Liver Transplantation
B-Lymphocytes
Hepatitis C
Viremia
Graft Survival
Splenectomy
Blood Donors
Cytomegalovirus
Hepacivirus
Immunosuppression
Transplantation
Rituximab
Lymphocytes
Transplants
Biopsy
Antigens
Liver
Therapeutics

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange. / Uchiyama, Hideaki; Mano, Yohei; Taketomi, Akinobu; Soejima, Yuji; Yoshizumi, Tomoharu; Ikegami, Toru; Shirabe, Ken; Maehara, Yoshihiko.

In: Transplantation, Vol. 92, No. 10, 27.11.2011, p. 1134-1139.

Research output: Contribution to journalArticle

@article{6829232c0f57440ca850f1457ecc4c01,
title = "Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange",
abstract = "Background. A novel immunosuppression protocol using rituximab and plasma exchange treatment was developed for ABO-incompatible living donor liver transplantation (ABO-I LDLT). The aim of this study was to investigate the kinetics of anti-blood type isoagglutinin titers and the number of blood B lymphocytes in ABO-I LDLT with the new protocol and their impact on the outcomes after ABO-I LDLT. Methods. Fifteen patients underwent ABO-I LDLT plus splenectomy with the new protocol between November 2005 and December 2010, and their data were retrospectively analyzed. Results. CD19-positive lymphocytes in the blood rapidly disappeared after rituximab treatment and began to recover approximately 6 months later. Anti-blood type isoagglutinin titers were lowered by pretransplant plasma exchange (2 3∼2 12→2 1∼2 8). Although the anti-donor blood type isoagglutinin titers remained consistently low after transplantation in comparison to the pretreatment levels, they persisted long after LDLT, whereas posttransplant biopsy specimens showed sustained A/B antigens on the graft livers. ABO-I hepatitis C virus-positive patients were prone to acceleration of hepatitis C viremia and cytomegalovirus antigenemia in comparison to the control patients. Conclusions. Although the new protocol for ABO-I LDLT yielded great success with 100{\%} graft survival, the acceptable anti-blood type isoagglutinin titers just before LDLT, and its application to hepatitis C-positive patients must be determined.",
author = "Hideaki Uchiyama and Yohei Mano and Akinobu Taketomi and Yuji Soejima and Tomoharu Yoshizumi and Toru Ikegami and Ken Shirabe and Yoshihiko Maehara",
year = "2011",
month = "11",
day = "27",
doi = "10.1097/TP.0b013e318231e9f8",
language = "English",
volume = "92",
pages = "1134--1139",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange

AU - Uchiyama, Hideaki

AU - Mano, Yohei

AU - Taketomi, Akinobu

AU - Soejima, Yuji

AU - Yoshizumi, Tomoharu

AU - Ikegami, Toru

AU - Shirabe, Ken

AU - Maehara, Yoshihiko

PY - 2011/11/27

Y1 - 2011/11/27

N2 - Background. A novel immunosuppression protocol using rituximab and plasma exchange treatment was developed for ABO-incompatible living donor liver transplantation (ABO-I LDLT). The aim of this study was to investigate the kinetics of anti-blood type isoagglutinin titers and the number of blood B lymphocytes in ABO-I LDLT with the new protocol and their impact on the outcomes after ABO-I LDLT. Methods. Fifteen patients underwent ABO-I LDLT plus splenectomy with the new protocol between November 2005 and December 2010, and their data were retrospectively analyzed. Results. CD19-positive lymphocytes in the blood rapidly disappeared after rituximab treatment and began to recover approximately 6 months later. Anti-blood type isoagglutinin titers were lowered by pretransplant plasma exchange (2 3∼2 12→2 1∼2 8). Although the anti-donor blood type isoagglutinin titers remained consistently low after transplantation in comparison to the pretreatment levels, they persisted long after LDLT, whereas posttransplant biopsy specimens showed sustained A/B antigens on the graft livers. ABO-I hepatitis C virus-positive patients were prone to acceleration of hepatitis C viremia and cytomegalovirus antigenemia in comparison to the control patients. Conclusions. Although the new protocol for ABO-I LDLT yielded great success with 100% graft survival, the acceptable anti-blood type isoagglutinin titers just before LDLT, and its application to hepatitis C-positive patients must be determined.

AB - Background. A novel immunosuppression protocol using rituximab and plasma exchange treatment was developed for ABO-incompatible living donor liver transplantation (ABO-I LDLT). The aim of this study was to investigate the kinetics of anti-blood type isoagglutinin titers and the number of blood B lymphocytes in ABO-I LDLT with the new protocol and their impact on the outcomes after ABO-I LDLT. Methods. Fifteen patients underwent ABO-I LDLT plus splenectomy with the new protocol between November 2005 and December 2010, and their data were retrospectively analyzed. Results. CD19-positive lymphocytes in the blood rapidly disappeared after rituximab treatment and began to recover approximately 6 months later. Anti-blood type isoagglutinin titers were lowered by pretransplant plasma exchange (2 3∼2 12→2 1∼2 8). Although the anti-donor blood type isoagglutinin titers remained consistently low after transplantation in comparison to the pretreatment levels, they persisted long after LDLT, whereas posttransplant biopsy specimens showed sustained A/B antigens on the graft livers. ABO-I hepatitis C virus-positive patients were prone to acceleration of hepatitis C viremia and cytomegalovirus antigenemia in comparison to the control patients. Conclusions. Although the new protocol for ABO-I LDLT yielded great success with 100% graft survival, the acceptable anti-blood type isoagglutinin titers just before LDLT, and its application to hepatitis C-positive patients must be determined.

UR - http://www.scopus.com/inward/record.url?scp=80855123587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855123587&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e318231e9f8

DO - 10.1097/TP.0b013e318231e9f8

M3 - Article

C2 - 21946174

AN - SCOPUS:80855123587

VL - 92

SP - 1134

EP - 1139

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -